Fulcrum Therapeutics (FULC) 10-K2022 FY Annual report

Filed: 9 Mar 23, 7:21am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: Addmedica, adherence, adjudicated, agonist, alloimmunization, antibody, AOC, Arroyo, Avidity, Bill, borrow, borrowing, breakdown, cap, CDPA, chelation, chemogenomic, chest, collateralized, Colorado, Connecticut, CPA, crossed, CTDPA, cutoff, cyber, cybersecurity, Disc, downturn, DROXIA, EEDi, email, ENDARI, espionage, etavopivat, exagamglogene, excise, expedient, expeditiously, FDORA, FTC, gram, Graphite, Gregory, headache, hematopoeitic, hemolytic, HPLC, HSCT, implicit, infertility, IRA, lip, malfunction, Mel, mishandling, monoclonal, nDec, noncurrent, OXBRYTA, peopulationopulation, potent, prompted, ratified, realign, realignment, Reblozyl, rental, resonance, Roche, RSA, runway, Russia, Russian, sabotage, Santiago, sapablursen, sibling, summer, Tourangeau, trait, transformative, trust, UCPA, Ukraine, unachieved, underway, unified, UPC, Utah, Virginia, VOC, winging, wire

Removed: accelerate, activate, activator, agnostic, aid, albuterol, alongside, ameliorate, analyze, antisense, Aruvant, automatic, balancing, Bellicum, biochemical, Biodistribution, Bioverativ, Bipartisan, blueprint, brain, Cadillac, captured, Celgene, certified, characterization, characterize, chimeric, chromatin, Clear, close, CNS, collected, concept, confirmed, conjunction, critically, CTA, defect, diseased, disseminate, donut, drugging, electorate, engrafted, engraftment, escalation, essential, experimentation, extracellular, faith, feasibility, feature, frame, functionally, fundamental, genome, guided, harbor, hematopoietic, heterogeneity, hole, host, Imara, immunodeficient, immunogenicity, implanted, infused, inhaled, inhibited, injected, inseverable, instilled, insurer, integrated, interact, interfering, intervene, intracellular, knocking, lab, landscape, leaving, link, mandate, map, matched, maximally, mechanistic, metabolic, modality, modeled, modeling, modify, Obama, optimization, Orchard, orthogonal, overview, partially, peak, percent, permeability, perturbagen, Peter, plasma, pooled, poverty, preempted, Prioritization, pursued, quantify, recommending, refinement, regulating, released, repealed, resale, restored, restoring, revising, RNA, ruling, selecting, sequencing, serve, session, signaling, static, stratification, sustained, tasked, tenant, Thomson, throughput, translatability, transmitted, transplantation, trillion, trough, unblinded, unclear, understand, understood, undesired, upregulate, varied, vasoocclusive, voted, wash, wholly, window

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated FULC transcripts

FULC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Fulcrum Therapeutics, Inc. (the “Company”) for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Esther Rajavelu, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: March 9, 2023	By:	/s/ Esther Rajavelu
		Esther Rajavelu
		Chief Financial Officer (Principal Financial Officer)